Buchumschlag

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)

Weitere Versionen anzeigen (1)

In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim to determine whether...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Betge, Johannes (VerfasserIn) , Chi-Kern, Jing (VerfasserIn) , Schulte, Nadine (VerfasserIn) , Belle, Sebastian (VerfasserIn) , Gutting, Tobias (VerfasserIn) , Burgermeister, Elke (VerfasserIn) , Jesenofsky, Ralf (VerfasserIn) , Ebert, Matthias (VerfasserIn) , Härtel, Nicolai (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 18 July 2018
In: BMC cancer
Year: 2018, Jahrgang: 18
ISSN:1471-2407
DOI:10.1186/s12885-018-4665-2
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12885-018-4665-2
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-018-4665-2
Volltext
Verfasserangaben:Johannes Betge, Jing Chi-Kern, Nadine Schulte, Sebastian Belle, Tobias Gutting, Elke Burgermeister, Ralf Jesenofsky, Martin Maenz, Ulrich Wedding, Matthias P. Ebert and Nicolai Haertel
Beschreibung
Zusammenfassung:In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim to determine whether treatment individualization by comprehensive geriatric assessments (CGAs) improves functional outcome of the patients.
Beschreibung:Gesehen am 04.09.2018
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-018-4665-2

Ähnliche Einträge